DELCATH TO REPORT FIRST QUARTER 2014 RESULTS ON MAY 7, 2014
April 30 2014 - 4:01PM
NEW YORK,
NY - April 30, 2014 - Delcath Systems, Inc. (NASDAQ:
DCTH) today announced that it will host a conference call and
webcast on Wednesday, May 7, 2014 at 4:30 p.m. ET to discuss its
financial results for the first quarter of 2014 ended March 31,
2014, and provide an update on recent corporate progress.
The dial-in numbers for the
conference call are 866-318-8612 (U.S. participants) and
617-399-5131 (international participants); both numbers require
passcode 78860495. To access the live webcast, go to the Events
& Presentations page on the Investor Relations section of the
Company's website at http://www.delcath.com/investors/events/.
A taped replay of the call will be
available beginning approximately two hours after the call's
conclusion and will be available for seven days. Dial-in numbers
for the replay are 888-286-8010 and 617-801-6888 for U.S. and
International callers, respectively. The replay passcode for both
U.S. and International callers is 52886168. An archived
webcast will also be available at
http://www.delcath.com/investors/events/.
About
Delcath Systems
Delcath Systems, Inc. is a
specialty pharmaceutical and medical device company focused on
oncology. Our proprietary product-Melphalan Hydrochloride for
Injection for use with the Delcath Hepatic Delivery System
(Melphalan HDS)-is designed to administer high dose chemotherapy to
the liver, while controlling the systemic exposure to those agents.
The Company's principal focus is on the treatment of primary
and metastatic liver cancers. In the United States, the
Melphalan/HDS system is considered a combination drug and device
product, and is regulated as a drug by the United States Food and
Drug Administration (FDA). The Melphalan/HDS system has not
been approved for sale in the United States. In Europe, our
proprietary system to deliver and filter melphalan hydrochloride is
marketed as a device under the trade name Delcath Hepatic
CHEMOSAT® Delivery
System for Melphalan (CHEMOSAT). In April 2012, we obtained
authorization to affix a CE Mark for the Generation Two
CHEMOSAT system. The right to affix the CE mark
allows the Company to market and sell the CHEMOSAT system in
Europe. The Company has initiated plans to investigate the
Melphalan/HDS system for primary liver cancer.
Contact Information: |
Investor Contact: |
Media Contact: |
Michael Polyviou/Patty Eisenhaur |
John Carter |
EVC Group |
EVC Group |
212-850-6020/951-316-0577 |
646-201-5431 |
###
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Delcath Systems, Inc via Globenewswire
HUG#1781761